Hartman Brunt
Internal Medicine · Baton Rouge, LANPI 1215431705
Payments from drug & device makers
Across 523 payments — averaging $28.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$4K
- AbbVie$4K
- Merck$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Johnson & Johnson$1K
- Pfizer$571
- plus $2K from 15 others
What the payments were for
- Consulting fees$3,75025%
- Travel & lodging$1,2879%
- Food & beverage$9,84966%
- Education$861%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 4 | $3,813 |
| AbbVie | 202 | $3,734 |
| Merck | 15 | $1,860 |
| Takeda Pharmaceuticals U.S.A., Inc. | 96 | $1,585 |
| Johnson & Johnson | 74 | $1,348 |
| Pfizer | 26 | $571 |
| Lilly USA, LLC | 30 | $543 |
| Daiichi Sankyo Inc. | 28 | $539 |
| Celltrion USA Inc. | 15 | $308 |
| Organon | 9 | $138 |
| Boehringer Ingelheim | 6 | $105 |
| La Jolla Pharmaceutical Company | 1 | $92 |
| Biocon Biologics Inc | 4 | $85 |
| Pharmacosmos Therapeutics Inc. | 3 | $69 |
| Aimmune Therapeutics, Inc. | 2 | $42 |
| Fresenius Kabi USA, LLC | 2 | $39 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Braintree Laboratories, Inc. | 1 | $23 |
| Exact Sciences | 1 | $19 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| GSK | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,973 in reported general payments places this provider in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 13 | $11,775 |
| Bupropion Hcl SrBupropion Hcl | 14 | $225 |
| Amitriptyline Hcl | 13 | $219 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $105 | $11,77513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Baton Rouge
- Katherine PearceBaton Rouge$12M
- Donna RyanBaton Rouge$991K
- Gertrude Chimeka AnyanwokeBaton Rouge$611K
- Deepesh PatelBaton Rouge$304K
- John SchwabBaton Rouge$122K
- Barret MurphyBaton Rouge$43K
- Brian GremillionBaton Rouge$27K
- Raoul ManalacBaton Rouge$27K
- Bradley MeekBaton Rouge$20K
- William SmithNew Orleans$50.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.